|
PureTech Health PLC on Tuesday highlighted positive phase 1 data from Seaport Therapeutics Inc for GlyphAgo, supporting plans to advance the experimental treatment into mid-stage trials for generalised anxiety disorder. The Boston, Massachusetts-based biotech and pharmaceutical firm said its founded entity Seaport reported favourable results from the multiple-ascending dose portion of a phase 1 proof-of-concept trial evaluating GlyphAgo, also known as SPT-320, in healthy volunteers. PureTech noted that the GlyphAgo programme and underlying Glyph platform were originally developed within the company before being transferred to Seaport. PureTech said repeat dosing demonstrated a safety, tolerability and pharmacokinetic profile consistent with previously reported data, with no serious or severe adverse events and no liver-related adverse events observed. GlyphAgo is a modified oral version of agomelatine, designed to improve bioavailability and reduce liver exposure by bypassing first-pass liver metabolism. Seaport said seven-day dosing achieved therapeutic agomelatine exposure levels at doses projected to avoid liver enzyme elevations and potentially reduce or eliminate the need for liver function testing. Seaport plans to begin a phase 2a proof-of-pharmacology study in the second half of 2026 in patients with generalised anxiety disorder and sleep disturbance. Top-line data are expected in early 2028. A separate phase 2b trial, designed to evaluate efficacy and safety and potentially support registration, is expected to start in the first half of 2027, with top-line results due by the end of 2028. Seaport Chief Executive Officer Daphne Zohar said the phase 1 data ‘substantially derisk our future clinical development approach and strengthen the differentiated profile of GlyphAgo’. Shares in PureTech Health were up 0.2% at 124.60 pence in London on Tuesday morning. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
